IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

The addition of anagliptin to insulin and metformin therapy may improve glycemic control in patients with type 2 diabetes while maintaining an acceptable safety profile.

Pregnant women with type 1 diabetes who used hybrid closed-loop insulin delivery with Control-IQ technology spent more time ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) ...

Children with diabetes who inhaled their mealtime doses of insulin did just as well as those who injected insulin under the ...

CHICAGO -- An investigational allogeneic stem cell-derived islet-cell therapy helped almost all patients with type 1 diabetes ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

Researchers at a recent American Diabetes Association meeting reported that efsitora, experimental once-weekly insulin, was comparable to daily insulins in nearly a thousand adults with type 2 ...

Today, findings from the QWINT-1 study found once-weekly insulin efsitora alfa (efsitora) lowered blood glucose (blood sugar) levels as effectively as daily basal insulin in insulin-naïve type 2 ...

Amanda Smith has kicked insulin to the curb in what experts are calling a milestone in the fight against Type 1 diabetes.